Leukotriene receptor antagonists benefit younger asthmatics, but their value is largely unknown in elderly asthmatics, stated author Michel Columbo
However, these associations were called into question when patients without asthma were enrolled [ 23 ], and when subtypes of sleeping disorders were defined as study outcomes
Race: Exercise-Induced Bronchoconstriction (EIB): Montelukast is indicated to prevent exercise-induced bronchoconstriction (EIB) in patients six years of age and older
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding
May also be used to treat exercise-induced bronchospasm (EIB) (this is shortness of breath that occurs only during exercise) in adults and children aged six years and older
In a double-blind, placebo-controlled, crossover, randomized add-on study, montelukast 10 mg was added for 14 days in a total of 72 adult asthmatics (age range 22-79 years), who were symptomatic despite treatment with Objective: The study aimed to establish the clinical effect of montelukast 10 mg in elderly patients with mild and moderate asthma compared to its effect on young adults
Find out how montelukast treats symptoms of asthma and how to take it
8 Although Bozek et al
However, these associations were called into question when patients without asthma were enrolled [ 23 ], and when subtypes of sleeping disorders were defined as study outcomes
Common side effects These common side effects of montelukast happen in more than 1 in 100 people
Background Little is known about asthma in the elderly as most studies of this condition have not included this patient group
Elderly: The pharmacokinetic profile and the oral bioavailability of a single 10-mg oral dose of montelukast are similar in elderly and younger adults
blurred vision
ear infection or earache
* To learn more about this side effect Methods: Elderly patients (>60 years old) with diagnoses of severe asthma were observed over 24 months of therapy: the first 12 months using inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) and the second 12 months with oral montelukast added in two-thirds of the patients, with the remaining third representing the control The purpose of this retrospective study was to determine the effects of long-term treatment with montelukast on chronic obstructive pulmonary disease (COPD) control in a cohort of patients with moderate to severe COPD
indigestion
Sánchez G, Buitrago D
However, this medicine should not be used to relieve an asthma attack that has already started
Aims: To investigate the effect of montelukast sodium plus budesonide on lung function, inflammatory factors, and immune levels in elderly asthma patients
Use in elderly The pharmacokinetic profile and the oral bioavailability of a single 10 mg oral dose of montelukast are similar in elderly and younger adults
Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 15 years of age and older A total of 106 drugs are known to interact with montelukast
In some cases, people may also experience anxiety, depression, or hallucinations
It is generally less preferred for this use than inhaled corticosteroids
In case of NPEs, the prevalence has been the highest in elderly people
Montelukast is an add-on treatment, which means you take it alongside your preventer inhaler
6 Hepatic Impairment
Although there is no study on the long-term therapeutic experience with montelukast for use in the elderly, this drug is generally safe and well tolerated
25 mg orally once a day in the evening
Comments: The recommended doses in pediatric patients 6 months to 12 years should not be exceeded
Montelukast sodium chewable tablets are a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 2 years of age and older ( 1
6%) of the asthmatic patients, 32 nonexposed, and five exposed to montelukast suffered a major cardiovascular event during the 3-year observation period
Methods A total of 180 patients with asthma were assigned into the The FDA is requiring a boxed warning for montelukast (sold under the brand name Singulair and in generic form) to strengthen an existing warning about the risk of neuropsychiatric events
one 10 mg tablet
This study is being done because there has been no placebo controlled study of montelukast focused on this group of patients
The plasma half-life of montelukast is Montelukast sodium is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 12 months of age and older ()
This makes breathing easier and prevents asthma attacks
Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older ( 1
Withdrawal Symptoms
The agency's risk-benefit calculus for montelukast has weighed its psychiatric risks against its wide use in treating many patients for asthma, which can be deadly
In the absence of
Effect of Montelukast 10 mg in Elderly Patients with Mild and Moderate Asthma Compared with Young Adults
It
Studies testing montelukast in the elderly population are very few 22, 36 – 39 and have several limitations
Warnings
It is a prescription medicine approved to prevent asthma attacks and for long-term treatment of asthma in
Like all medicines, montelukast can cause side effects, although not everyone gets them
Professional info
Montelukast use in adults with asthma is significantly associated with increased risk for neuropsychiatric events, especially among younger adults aged 18 to